AI Article Synopsis
Article Abstract
Sera of normal subjects and AIDS patients living in Minsk and Odessa were tested for antibodies to hazardous viral infections Lassa, Marburg, and Ebola. Four to 16% of examinees were seropositive to Ebola virus, 0.8 to 2.3% to Lassa, and up to 0.8% to Marburg virus. Common B-epitopes were found in viruses belonging to different families: Lassa, Ebola, and HIV. Antibodies specific to these viruses antigens were found in the reference sera to influenza A and B, respiratory syncytial virus, and adenovirus. Sera of convalescents after malaria and of AIDS patients contained antibodies to Lassa virus.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Molecular detection of dengue virus from febrile patients in Ghana.
BMC Infect Dis
December 2024
Tokyo Medical and Dental University, Tokyo, Japan.
Background: Viral hemorrhagic fevers (VHFs) belong to a group of viral infectious diseases that interfere with the blood's clotting mechanism. VHF has a wide host range, including bats, rodents, or arthropods such as mosquitoes and ticks. Most VHFs emerge suddenly as outbreaks, making it difficult to predict occurrence.
View Article and Find Full Text PDFEnabling laboratory readiness and preparedness for the evaluation of suspected viral hemorrhagic fevers: development of a laboratory toolkit.
Infect Control Hosp Epidemiol
October 2024
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Article Synopsis
- - The document discusses the significance of preparing healthcare facilities in the U.S. to evaluate and care for patients suspected of having viral hemorrhagic fevers (VHFs) like Ebola and Marburg, given their potential for serious illness and transmission.
- - The objective is to enhance readiness in labs for the initial care of these patients using a quality improvement model to create a toolkit tailored for frontline healthcare facilities.
- - This toolkit includes protocols for infection control, waste management, and necessary laboratory testing, aiming to ensure safe handling and high-quality care for VHF suspects in emergency settings.
Inactivation Validation of Ebola, Marburg, and Lassa Viruses in AVL and Ethanol-Treated Viral Cultures.
Viruses
August 2024
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
High-consequence pathogens such as the Ebola, Marburg, and Lassa viruses are handled in maximum-containment biosafety level 4 (BSL-4) laboratories. Genetic material is often isolated from such viruses and subsequently removed from BSL-4 laboratories for a multitude of downstream analyses using readily accessible technologies and equipment available at lower-biosafety level laboratories. However, it is essential to ensure that these materials are free of viable viruses before removal from BSL-4 laboratories to guarantee sample safety.
View Article and Find Full Text PDFDefining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.
Cell Rep
September 2024
Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA 92037, USA. Electronic address:
Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of vaccines that can elicit strong neutralizing antibody responses. However, Lassa vaccine candidates have generally been unsuccessful at doing so, and the associated antibody responses to these vaccines remain poorly characterized.
View Article and Find Full Text PDFAptamer and aptasensor technology for diagnosis of infectious diseases: A mini review.
Indian J Med Microbiol
September 2024
Department of Microbiology SDM College of Medical Sciences and Hospital, Shri Dharmasthala Manjunatheshwara (SDM) University, Dharwad, 580009, Karnataka, India. Electronic address:
Article Synopsis
- - Aptamers, first discovered in the 1990s, are emerging as powerful diagnostic tools but are not widely recognized in the medical field, despite their potential to revolutionize disease detection.
- - The article highlights several endemic and epidemic diseases recognized by the WHO, such as Ebola and Zika, that could benefit from aptamer technology for quicker, more accessible diagnoses beyond tertiary care centers.
- - The review emphasizes recent advances in aptamer technology and engineering, showcasing its effectiveness for diagnosing various infectious and non-infectious diseases through innovative optical and electrochemical sensing methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!